Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Frida Group Aps operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This figure indicates a focused prosecution stage for the company's pharmaceutical technologies. For a practitioner, this volume suggests that the current legal efforts are concentrated on a single set of biotechnological claims at the USPTO.
The examination of these filings is conducted by a distinct examiner in a single art unit. This concentration suggests that the company's biotechnological innovations are being reviewed through a single administrative path. MATTISON, LORI K is the busiest examiner for the portfolio. The involvement of a single art unit ensures that the company's innovations are evaluated within a consistent technical and administrative framework.
MATTISON, LORI K is currently managing 1 busiest examiner pending office action. Since there is only a single pending action overall, the feedback from MATTISON, LORI K is the primary factor in the portfolio's immediate progress. Practitioners should prepare responses that address the specific concerns of MATTISON, LORI K and the standards of the art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATTISON, LORI K | 1 | 14.7% | +26.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006081 | ANTIVIRAL SURFACES COMPRISING POLYOXOMETALATES AND ZINC MOLYBDATE | MATTISON, LORI K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006081 | ANTIVIRAL SURFACES COMPRISING POLYOXOMETALATES AND ZINC MOLYBDATE | MATTISON, LORI K | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18006081 | ANTIVIRAL SURFACES COMPRISING POLYOXOMETALATES AND ZINC MOLYBDATE | MATTISON, LORI K | 1619 | §103§112 | Final Rejection | — | Pending | Jan 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial